Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia

Conclusion Total health care costs are higher for episodes of TKI treatment failure than those of ongoing treatment, largely as a result of costly medical (nonpharmacologic) services. Avoiding treatment failure by optimal CML management may reduce health care costs. Micro-Abstract To understand the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), episodes of TKI treatment failure in the 1 year after initiation were matched to those without failure. Failures had significantly higher health care resource use and costs. The high economic burden of TKI treatment failure reinforces the importance of optimal management in CML.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research